1-(3,4-dichlorophenyl)-3,4-dimethyl-4-(4-hydroxyphenyl)-2-thioxoimidazolidin-5-one | 959690-46-1

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 唑烷类
• 英文名称: 1-(3,4-dichlorophenyl)-3,4-dimethyl-4-(4-hydroxyphenyl)-2-thioxoimidazolidin-5-one
• 英文别名: 3-(3,4-Dichlorophenyl)-5-(4-hydroxyphenyl)-1,5-dimethyl-2-sulfanylideneimidazolidin-4-one
• CAS: 959690-46-1
• 化学式: C₁₇H₁₄Cl₂N₂O₂S
• 分子量: 381.282
• InChiKey: YPONBLYNQFHCLA-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  4.3
• 重原子数：
  24
• 可旋转键数：
  2
• 环数：
  3.0
• sp3杂化的碳原子比例：
  0.18
• 拓扑面积：
  75.9
• 氢给体数：
  1
• 氢受体数：
  3

反应信息

• 作为产物：
  描述：

  methyl 2-(4-acetoxyphenyl)-2-bromopropionate 在 三乙胺 作用下， 以 四氢呋喃 、 乙醇 为溶剂， 反应 18.5h， 生成 1-(3,4-dichlorophenyl)-3,4-dimethyl-4-(4-hydroxyphenyl)-2-thioxoimidazolidin-5-one
  参考文献：
  名称：

  Discovery of Diarylhydantoins as New Selective Androgen Receptor Modulators

  摘要：

  A novel selective androgen receptor modulator scaffold has been discovered through structural modifications of hydantoin antiandrogens. Several 4-(4-hydroxyphenyl)-N-arylhydantoins displayed partial agonism with nanomolar in vitro potency in transactivation experiments using androgen receptor (AR) transfected cells. In a standard castrated male rat model, several compounds showed good anabolic activity on levator ani muscle, dissociated from the androgenic activity on ventral prostate, after oral dosing at 30 mg/kg. (+)-4-[3,4-Dimethyl-2,5-dioxo-4-(4-hydroxyphenyl)imidazolidin-1-yl]-2-(trifluoromethyl)benzonitrile ((+)-11b) displayed anabolic potency with a strong dissociation between levator ani muscle and ventral prostate (A(50) = 0.5 mg/kg vs 70 mg/kg). The binding modes of two compounds, including (+)-11b, within the AR ligand-binding domain have been studied by cocrystallization experiments using a coactivator-like peptide. Both compounds bound to the same site, and the overall structures of the AR were very similar.

  DOI：

  10.1021/jm300249m

文献信息

• Imidazolidine Derivatives, Uses Therefor, Preparation Thereof and Compositions Comprising Such
  申请人：Nique Francois

  公开号：US20100063120A1

  公开（公告）日：2010-03-11

  Compounds of formula (I): wherein X is O or S, R 1 is acyl, aldehyde, cycloalkyl, an optionally substituted alkyl, alkenyl or alkynyl, R 2 is H. alkyl, hydroxyalkyl, haloalkyl, alkenyl, or alkynyl; substituted alkyl; alkylcarbonyl; R 3 and R 4 are H, halogen, alkyl, alkenyl, alkynyl, alkoxyl, alkylthio, hydroxyalkyl, haloalkyl, haloalkenyl, or haloalkynyl; or R 3 and R 4 form an, optionally aromatic or heterocyclic, optionally substituted ring, R 5 is H, halogen, trifluoromethyl, —CN, or —NO2; not all of R 3 , R 4 , and R 5 being H, R 6 and R 9 are H, halogen, OH; alkyl. hydroxyalkyl, alkoxyl, thioalkyl, haloalkyl, alkenyl, or alkynyl; R 7 and R 8 are H, halogen, OH, SH; alkoxyl or alkylthio optionally substituted by OH and/or halogen; one of R 7 and R 8 not being H or halogen; or one of R 7 and R 8 is a pharmaceutically acceptable ester or thioester grouping, or R 6 is C 1-3 -alkyl or, together with either R 1 or R 2 , represents C 1-3 alkylene or alkenylene linking group, optionally substituted by methyl, trifluoromethyl, OH, or halogen, and pharmaceutically acceptable salts and esters thereof, are useful as selective androgen modulators.

  式(I)的化合物：其中X为O或S，R1为酰基，醛基，环烷基，或可选择地取代的烷基，烯基或炔基，R2为H，烷基，羟基烷基，卤代烷基，烯基或炔基；取代烷基；烷基羰基；R3和R4为H，卤素，烷基，烯基，炔基，烷氧基，烷硫基，羟基烷基，卤代烷基，卤代烯基，或卤代炔基；或R3和R4形成一个，可选择的芳香或杂环，可选择地取代的环，R5为H，卤素，三氟甲基，-CN，或-NO2；R3，R4和R5中不全为H，R6和R9为H，卤素，羟基；烷基，羟基烷基，烷氧基，硫代烷基，卤代烷基，烯基，或炔基；R7和R8为H，卤素，羟基，硫氢基；烷氧基或烷硫基，可选择地由羟基和/或卤素取代；R7和R8中的一个不为H或卤素；或R7和R8中的一个为药用可接受的酯或硫酯基团，或R6为C1-3-烷基或，与R1或R2中的任一者一起，代表C1-3烷基或烯基链连接基，可选择地由甲基，三氟甲基，羟基，或卤素取代，以及其药用可接受的盐和酯，可用作选择性雄激素调节剂。
• IMIDAZOLIDINE DERIVATIVES, USES THEREFOR, PREPARATION THEREOF AND COMPOSITIONS COMPRISING SUCH
  申请人：NIQUE Francois

  公开号：US20100210699A1

  公开（公告）日：2010-08-19

  Compounds of formula (I): wherein X is O or S, R 1 is acyl, aldehyde, cycloalkyl, an optionally substituted alkyl, alkenyl or alkynyl, R 2 is H, alkyl, hydroxyalkyl, haloalkyl, alkenyl, or alkynyl; substituted alkyl; alkylcarbonyl; R 3 and R 4 are H, halogen, alkyl, alkenyl, alkynyl, alkoxyl, alkylthio, hydroxyalkyl, haloalkyl, haloalkenyl, or haloalkynyl; or R 3 and R 4 form an, optionally aromatic or heterocyclic, optionally substituted ring, R 5 is H, halogen, trifluoromethyl, —CN, or —NO 2 ; not all of R 3 , R 4 , and R 5 being H, R 6 and R 9 are H, halogen, OH; alkyl, hydroxyalkyl, alkoxyl, thioalkyl, haloalkyl, alkenyl, or alkynyl; R 7 and R 8 are H, halogen, OH, SH; alkoxyl or alkylthio optionally substituted by OH and/or halogen; one of R 7 and R 8 not being H or halogen; or one of R 7 and R 8 is a pharmaceutically acceptable ester or thioester grouping, or R 6 is C 1-3 -alkyl or, together with either R 1 or R 2 , represents C 1-3 alkylene or alkenylene linking group, optionally substituted by methyl, trifluoromethyl, OH, or halogen, and pharmaceutically acceptable salts and esters thereof, are useful as selective androgen modulators.

  化合物式（I）：其中X为O或S，R1为酰基，醛基，环烷基，可选取代的烷基，烯基或炔基，R2为H，烷基，羟基烷基，卤代烷基，烯基或炔基；取代烷基；烷基羰基；R3和R4为H，卤素，烷基，烯基，炔基，烷氧基，烷硫基，羟基烷基，卤代烷基，卤代烯基或卤代炔基；或R3和R4形成一个可选的芳香或杂环，可选取代的环，R5为H，卤素，三氟甲基，—CN或—NO2；R3，R4和R5不全为H，R6和R9为H，卤素，OH；烷基，羟基烷基，烷氧基，硫代烷基，卤代烷基，烯基或炔基；R7和R8为H，卤素，OH，SH；烷氧基或烷硫基，可选取代为OH和/或卤素；R7和R8中的一个不为H或卤素；或R7和R8中的一个是药物可接受的酯或硫酯基团，或R6为C1-3烷基或与R1或R2中的一个共同表示C1-3烷基或烯基链连接基团，可选取代为甲基，三氟甲基，OH或卤素，以及其药物可接受的盐和酯，用作选择性雄激素调节剂。
• US8168667B2
  申请人：——

  公开号：US8168667B2

  公开（公告）日：2012-05-01
• Discovery of Diarylhydantoins as New Selective Androgen Receptor Modulators
  作者：François Nique、Séverine Hebbe、Christophe Peixoto、Denis Annoot、Jean-Michel Lefrançois、Eric Duval、Laurence Michoux、Nicolas Triballeau、Jean-Michel Lemoullec、Patrick Mollat、Maxime Thauvin、Thierry Prangé、Dominique Minet、Philippe Clément-Lacroix、Catherine Robin-Jagerschmidt、Damien Fleury、Denis Guédin、Pierre Deprez

  DOI：10.1021/jm300249m

  日期：2012.10.11

  A novel selective androgen receptor modulator scaffold has been discovered through structural modifications of hydantoin antiandrogens. Several 4-(4-hydroxyphenyl)-N-arylhydantoins displayed partial agonism with nanomolar in vitro potency in transactivation experiments using androgen receptor (AR) transfected cells. In a standard castrated male rat model, several compounds showed good anabolic activity on levator ani muscle, dissociated from the androgenic activity on ventral prostate, after oral dosing at 30 mg/kg. (+)-4-[3,4-Dimethyl-2,5-dioxo-4-(4-hydroxyphenyl)imidazolidin-1-yl]-2-(trifluoromethyl)benzonitrile ((+)-11b) displayed anabolic potency with a strong dissociation between levator ani muscle and ventral prostate (A(50) = 0.5 mg/kg vs 70 mg/kg). The binding modes of two compounds, including (+)-11b, within the AR ligand-binding domain have been studied by cocrystallization experiments using a coactivator-like peptide. Both compounds bound to the same site, and the overall structures of the AR were very similar.